Möchten Sie immer auf dem neuesten Stand bleiben?

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched...

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Silver Spring, Md., May 29, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for...

MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes

Omniscient (o8t®) secures $27.2M Series D funding to scale its AI-powered Quicktome® brain mapping platform and accelerate personalized brain care globally

Icelandirect contract manufacturer of supplements, vitamins, and nutraceuticals for human and pet brands, completes its FSSC 22000 Version 6 certification.

Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”;...

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.